Report Company Directory

Corbion NV

• Corbion and Kuehnle AgroSystems join forces to develop natural Astaxanthin from algae fermentation by GlobeNewsWire
• European Chemicals Sector "Investor positioning in European Chemicals" Haire by UBS AG
• ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 04/08/2025 by Oddo BHF
• ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 04/08/2025 by Oddo BHF
• Corbion N.V. : TP cut to € 25 (from € 30); Outperform maintained, but patience required by Oddo BHF
• ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 07/31/2025 by Oddo BHF
• ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 31/07/2025 by Oddo BHF
• Corbion N.V. : Solid EBITDA delivery in Q2 2025; Outlook reiterated for the full year by Oddo BHF
• Benelux Morning Notes by ING Financial Markets
• Morning Notes : ABI BB, ARGX BB, BEKB BB, CRBN NA, DSFIR NA, ENX FP, FAGR BB, FLOW NA, INGA NA, ONTEX BB, UCB BB, AZE BB, SYENS BB by KBC Securities

Corbus Pharmaceuticals Holdings Inc

• Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences by GlobeNewsWire
• Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates by GlobeNewsWire
• Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis by GlobeNewsWire
• Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2021 Virtual Congress by GlobeNewsWire
• CORBUS PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING by GlobeNewsWire
• Corbus Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Updates by GlobeNewsWire
• Corbus Pharmaceuticals to Present at Three Upcoming Investor Conferences by GlobeNewsWire
• Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results by GlobeNewsWire
• An unfavourable environment weighs on CORBUS PHARMS.HOLDINGS, which sees a downgrade to Negative by TheScreener
• Corbus Pharmaceuticals Licenses Two Integrin Targeting mAbs Further Expanding Pipeline into Cancer and Fibrotic Diseases by GlobeNewsWire

CORBUS PHARMACEUTICALS HOLDINGS INC.

• Orforglipron Surprised to the Upside in Higher-Risk Population; Diabetes Could Be a Key Demographic for Commercial Success by William Blair
• Fast Forward No. 770 by William Blair
• Critical Mass – Second Quarter 2025 Update of Obesity Drug Developers Within William Blair’s Coverage Universe by William Blair
• Fast Forward No. 769 by William Blair
• Fast Forward No. 768 by William Blair
• Did Weight Loss Plateau Early as Observed in Diabetes for Orforglipron? Lilly’s Miss Could Create an Opening for Competitors by William Blair
• Q2 Financials; Meaningful CRB-701 Data Update at ESMO by Wedbush
• Company Enters a Catalyst-Rich Period, With All Three Assets Across Oncology and Obesity Expected to Release Data by Year-End by William Blair
• Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update by GlobeNewsWire
• Fast Forward No. 767 by William Blair

Corby Distillers Ltd. Cl A Vtg

• Corby Spirit And Wine Ltd: 1 director by SmartInsider
• Ford Equity International Rating and Forecast Report by Ford Equity Research

CORBY SPIRIT & WINE LTD